Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Livmarli

Chemical Namemaralixibat
Dosage FormSolution (oral; 9.5 mg/mL)
Drug ClassInhibitors
SystemDigestive
CompanyMirum Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Livmarli (maralixibat) Prescribing Information.2021Mirum Pharmaceuticals Inc., Foster City, CA
Document TitleYearSource
A maralixibat expanded access program for patients with cholestatic pruritus associated with Alagille Syndrome (ALGS).2021U.S. National Library of Medicine